| Literature DB >> 26060913 |
Nagwa Mohamed Mahrous Hamada1, Nadia Yousef Megally Abdo2.
Abstract
The present work deals with the synthesis of acetoxysulfonamide pyrazole derivatives, substitutedEntities:
Keywords: anti-inflammatory; antimicrobial activity; antioxidant; chalcones; isonicotinic acid hydrazide; sulfonamide pyrazole
Mesh:
Substances:
Year: 2015 PMID: 26060913 PMCID: PMC6272688 DOI: 10.3390/molecules200610468
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structural formula of celecoxib.
Scheme 1Synthesis of some novel substituted pyrazoles.
Determination of zone of inhibition and minimum inhibitory concentrations (MIC).
| Compound No. | Zone of Inhibition (mm) | Minimum Inhibitory Concentration (MIC) mg/mL | ||
|---|---|---|---|---|
| - | 15 | - | - | |
| - | 15 | - | - | |
| 21 | 20 | 0.1 | 0.05 | |
| 15 | 18 | 0.063 | 0.063 | |
| - | 15 | - | - | |
| 19 | 22 | 0.063 | 0.031 | |
| 18 | 25 | 0.125 | 0.031 | |
| 22 | 26 | 0.05 | 0.05 | |
| 18 | 20 | 0.063 | 0.125 | |
| 17 | 17 | - | - | |
| - | 15 | - | - | |
| - | 15 | - | - | |
| 21 | 24 | 0.05 | 0.05 | |
| - | 15 | - | - | |
| 17 | 17 | - | - | |
| - | 20 | - | 0.25 | |
| - | 15 | - | - | |
| 17 | 20 | 0.1 | 0.05 | |
| 14 | 20 | 0.12 | 0.5 | |
| 12 | 15 | - | - | |
| Rifampicin | 32 | - | - | - |
| Ampicillin | 30 | - | - | - |
| DMSO | - | 14 | - | - |
-: No activity.
Determination of minimum bactericidal concentration (MBC) of the chloro series.
| Concentrations mg/mL | 1 | 0.50 | 0.25 | 0.125 | 0.063 | 0.031 | 1 | 0.50 | 0.25 | 0.125 | 0.063 | 0.031 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Microorganism Growth | ||||||||||||
| − | − | * | + | + | + | − | * | + | + | + | + | |
| − | − | * | + | + | + | − | − | * | + | + | + | |
| − | * | + | + | + | + | − | − | − | * | + | + | |
| − | − | * | + | + | + | − | − | − | * | + | + | |
−: No turbidity; +: Turbidity; *: MBC
Scheme 2Reactions of DPPH.
In vitro antioxidant activity data (DPPH scavenging).
| Compound No. | Mean Absorbance ± S.D.* at Different Concentrations | Efficacy at 0.25/0.25 Vitamin C | |||
|---|---|---|---|---|---|
| 0.25 mg/mL | 0.5 mg/mL | 0.75 mg/mL | 1 mg/mL | ||
| 9.4 ± 0.5 | −65 ± 3.5 | −69 ± 5.2 | −88 ± 3.5 | 0.13 | |
| 58 ± 3.2 | 60 ± 2.5 | 91 ± 4.2 | 94 ± 6.5 | 0.81 | |
| 20 ± 2.4 | 12 ± 1.2 | −12 ± 1.2 | −5 ± 0.5 | 0.28 | |
| 78.8 ± 1.2 | 43.5 ± 2.5 | 31.8 ± 3.1 | −69 ± 6 | 1.1 | |
| 64.7 ± 4.3 | 51 ± 2.3 | 21 ± 2.5 | −7 ± 0.8 | 0.9 | |
| Vitamin C | 72 ± 2.5 | 76 ± 1.8 | 89 ± 2.1 | 94 ± 2.8 | |
* S.D. = Standard deviation (Average of three determination).
In vitro anti-inflammatory activity data (NO scavenging).
| Compound No. | Mean Absorbance ± S.D.* at Different Concentrations | Efficacy at 0.25/0.25 Vitamin C | |||
|---|---|---|---|---|---|
| 0.25 mg/mL | 0.5 mg/mL | 0.75 mg/mL | 1 mg/mL | ||
| 36 ± 1.3 | 38 ± 2.1 | 41 ± 4.1 | 44 ± 1.5 | 0.88 | |
| 17 ± 1.7 | 19 ± 1.2 | 25 ± 1.5 | 29 ± 1.8 | 0.4 | |
| 7 ± 1.1 | 14 ± 1.2 | 25 ± 1.5 | 47 ± 3.5 | 0.94 | |
| 19 ± 1.9 | 36 ± 3.2 | 58 ± 2.4 | 74 ± 4.5 | 1.5 | |
| 26 ± 1.9 | 34 ± 1.5 | 42 ± 2.5 | 62 ± 5.2 | 1.03 | |
| Vitamin C | 50 ± 1.2 | ||||
* S.D. = Standard deviation (Average of three determination).